PriceTargets.com logo

AzurRx BioPharma - AZRX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.12 As of 04/23/2024 01:00 AM ET
▲ +0.21 (7.22%)
Get New AzurRx BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AZRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AZRX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for AzurRx BioPharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.12.

This chart shows the closing price for AZRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in AzurRx BioPharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/2/2021HC WainwrightReiterated RatingBuy$20.00Medium
4/14/2021HC WainwrightReiterated RatingBuy$25.00High
4/1/2021Maxim GroupInitiated CoverageBuy$30.00N/A
4/1/2021Roth CapitalLower TargetBuy$70.00 ➝ $50.00High
4/1/2021HC WainwrightLower TargetBuy$35.00 ➝ $25.00High
2/10/2021HC WainwrightBoost TargetBuy$20.00 ➝ $35.00Low
1/22/2021HC WainwrightReiterated RatingBuy$20.00High
1/6/2021Dawson JamesDowngradeBuy ➝ NeutralN/A
8/13/2020Maxim GroupReiterated RatingBuy$30.00High
5/20/2020HC WainwrightReiterated RatingBuy$20.00Low
4/22/2020HC WainwrightReiterated RatingBuy$20.00Medium
4/1/2020HC WainwrightLower TargetBuy$50.00 ➝ $20.00High
1/24/2020Roth CapitalReiterated RatingBuyHigh
1/10/2020HC WainwrightReiterated RatingBuy$50.00High
10/18/2019HC WainwrightSet TargetBuy$50.00High
10/15/2019Maxim GroupSet TargetBuy$30.00N/A
10/11/2019HC WainwrightSet TargetBuy$50.00Low
9/26/2019HC WainwrightLower TargetBuy$60.00 ➝ $50.00High
8/14/2019HC WainwrightReiterated RatingBuy$60.00Medium
7/29/2019HC WainwrightReiterated RatingBuyMedium
6/11/2019National SecuritiesInitiated CoverageBuy ➝ Buy$90.00High
5/24/2019HC WainwrightReiterated RatingBuy$70.00Low
4/24/2019Maxim GroupReiterated RatingBuy$50.00Low
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
AzurRx BioPharma logo
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.
Read More

Today's Range

Now: $3.12
Low: $2.90
High: $3.40

50 Day Range

MA: $4.04
Low: $2.40
High: $41.00

52 Week Range

Now: $3.12
Low: $3.36
High: $26.30

Volume

151,007 shs

Average Volume

628,703 shs

Market Capitalization

$29.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of AzurRx BioPharma?

The following Wall Street sell-side analysts have issued reports on AzurRx BioPharma in the last year:
View the latest analyst ratings for AZRX.

What is the current price target for AzurRx BioPharma?

0 Wall Street analysts have set twelve-month price targets for AzurRx BioPharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for AzurRx BioPharma in the next year.
View the latest price targets for AZRX.

What is the current consensus analyst rating for AzurRx BioPharma?

AzurRx BioPharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AZRX.

What other companies compete with AzurRx BioPharma?

Other companies that are similar to AzurRx BioPharma include Aprea Therapeutics, Lexaria Bioscience, Spruce Biosciences, Daré Bioscience and NRx Pharmaceuticals. Learn More about companies similar to AzurRx BioPharma.

How do I contact AzurRx BioPharma's investor relations team?

AzurRx BioPharma's physical mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company's listed phone number is (649) 699-7855 and its investor relations email address is [email protected]. The official website for AzurRx BioPharma is www.azurrx.com. Learn More about contacing AzurRx BioPharma investor relations.